Full-Time
Mechanical Engineer
Posted on 7/5/2026
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
Compensation Overview
$96.5k - $183.5k/yr
Tempe, AZ, USA
In Person
US & Puerto Rico only.
Bachelor's, Master's
 Mechanical Engineering |
|---|
Get referred to AbbVie
See people who can refer or advise you
- Bachelor’s Degree in Mechanical Engineering and typically 10 years of experience, Master’s Degree or equivalent education and typically 8 years of experience.
- Support design and development activities for injection drug delivery devices
- Perform mechanical analysis, prototyping, testing, and troubleshooting of device components and assemblies
- Evaluate device performance, identify failure modes, and support root cause investigations
- Assist with verification, validation, and technical transfer activities
- Collaborate with R&D, manufacturing, quality, regulatory, and suppliers to advance device programs
- Generate and review technical documentation, test reports, specifications, and protocols
- Support change control, risk assessments, and continuous improvement efforts
- Contribute to device platform strategy, robustness, and manufacturability
- Ensure all work is conducted in compliance with safety, quality, and applicable regulatory requirements (e.g. 21 CFR 820 / Design Controls)
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 sales beat.
- RINVOQ won July 2026 EU approvals for vitiligo and alopecia areata.
- Apogee is expected to close in Q3 2026, deepening AbbVie’s pipeline.
What critics are saying
- HUMIRA fell 36% in Q2 2026, and biosimilar erosion continues into 2027.
- Epcoritamab missed its U.S. Phase 3 survival endpoint on July 23, 2026.
- SKYRIZI’s 2033 patent cliff would gut AbbVie’s replacement for Humira if execution slips.
What makes AbbVie unique
- AbbVie’s SKYRIZI and RINVOQ generated $8.8 billion in Q2 2026, replacing Humira.
- The Apogee acquisition adds long-acting immunology assets for atopic dermatitis and asthma.
- AbbVie’s scale, cash flow, and aesthetics franchise fund acquisitions and dividends.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↑ 3%2 year growth
↑ 3%AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.
Genmab and AbbVie confirmed on 23 July that their jointly developed bispecific antibody epcoritamab failed to meet its primary endpoint in a Phase 3 trial. The study evaluated epcoritamab monotherapy against chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. In the US, where overall survival was the sole primary endpoint, the trial did not demonstrate statistically significant improvement. Despite the setback, epcoritamab maintains its accelerated FDA approval. Both companies will review the full data set with regulators to determine next steps. Genmab reported H1 2026 revenue of $2.051 billion, up 25% year-over-year, raising full-year guidance to $4.325–$4.525 billion. AbbVie posted Q2 2026 net revenues of $16.99 billion, up 10.2%, driven by its immunology portfolio generating $8.79 billion.
AbbVie's strong operational performance has not translated into stock gains matching its pharmaceutical peers. The drugmaker achieved 10.4% revenue growth and a 34% operating margin over the past year, ranking second among six key competitors. Despite these results, AbbVie's stock returned 30% over twelve months, trailing Merck's 67% and Johnson & Johnson's 54%. The disconnect appears rooted in market concerns about future competition. Analysts questioned management about competitive dynamics for key immunology drugs SKYRIZI and RINVOQ, which each grew sales 24%. The company trades at 70.1 times earnings but lacks the premium stock performance of peers. The market seems to be pricing in risks that AbbVie's high-performing drugs will face tougher competition, potentially eroding current growth rates and margins.
Why Bristol Myers Squibb is investing $2.3bn in Texas. August 12, 2026 Bristol Myers Squibb is investing US$2.3bn in a new manufacturing facility in Houston, Texas, aiming to reinforce the US's pharmaceutical supply chain Bristol Myers Squibb (BMS) says it will invest US$2.3bn into a new manufacturing hub in Houston, Texas to boost its domestic pharmaceutical supply chain. The plan is part of the company's five year commitment to invest US$40bn in the US across research and development, domestic manufacturing and technology. Christopher Boerner, CEO of BMS, says: "As part of our US$40bn commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs." What will the investment create? BMS says its new hub will allow the company to manufacture multiple types of medicine including small molecules, biologics and antibody drug conjugates. The campus will be located at Generation Park, spanning across 600,000 square feet, and aims to initially create around 500 skilled jobs. Building this new facility will allow the company to manufacture multiple types of medicine including small molecules, biologics and antibody drug conjugates. Initial plans are expected to bring construction between 2027 and 2030, during which BMS is expecting to create around 2,000 construction and other indirect jobs. BMS currently has seven manufacturing and commercial manufacturing facilities across the world. US pharmaceutical supply chain. According to research from the US Pharmacopeia in 2024, more than 50% of active pharmaceutical ingredient (API) production comes from Europe and India, while the US accounts for just 12%. The new BMS facility is expected to lower reliance on overseas production and develop the US supply chain. US Secretary of Commerce Howard Lutnick says: "Bristol Myers Squibb's US$2.3bn investment in Texas will create hundreds of high-paying jobs and strengthen our pharmaceutical supply chains, ensuring America is never reliant on foreign sources for critical medicines." In January 2026, Abbvie committed US$100bn towards domestic research, development and capital investments over a 10 year period. This funding has already seen some allocations, including across two API plants in Illinois, and another US$1.4bn for a manufacturing campus focusing on immunology, neuroscience and oncology products in North Carolina. Abbvie has also acquired a manufacturing facility in Arizona, where it designated US$175m to expand capacity for drug delivery devices. Company Portals
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics in June 2026, aiming to strengthen its drug pipeline. The biopharmaceutical company reported FY 2025 revenue of nearly $61.2 billion, up roughly 8.6% year-on-year. Net income reached close to $4.2 billion, reflecting a net margin of approximately 6.9%, down from 7.6% the previous year. Free cash flow for the period was nearly $17.8 billion. CVS Health reported FY 2025 revenue of approximately $402.1 billion, representing growth of nearly 7.8%. The integrated healthcare provider serves around 37 million medical members and manages 1.9 billion prescriptions annually through its Health Services segment. Net income was close to $1.8 billion, yielding a net margin of roughly 0.4%, down from 1.2% in FY 2024.